Law Offices of Thomas J. Lamb, P.A.

Law Offices of Thomas J. Lamb, P.A. Blogs

Latest from Law Offices of Thomas J. Lamb, P.A.

Significant Increased Risk Of Cardiotoxic Events Such As Myocardial Infarction, Stroke, And Cardiovascular Death   (Posted by Tom Lamb at DrugInjuryWatch.com)   In the medical literature, more attention is paid to the cardiovascular safety of Imbruvica (ibrutinib), this time with the focus being on Imbruvica-related hypertension and associated serious side effects such as arrhythmias, myocardial infarction, stroke, heart failure, and cardiovascular death. The medical journal Blood, from the American Society of Hematology, published this…
Cardiovascular Adverse Drug Reactions Often Occurred Soon After Administration Of Imbruvica, According To Recent Medical Study   (Posted by Tom Lamb at DrugInjuryWatch.com)   Patients treated with Imbruvica (ibrutinib) had an increased occurrence of severe and sometimes fatal cardiac events, with Imbruvica cardiovascular toxicities suspected in these higher serious side effects rates, according to a recent clinical trial where Imbruvica therapy was compared with conventional chemotherapy. This medical journal article, “Cardiovascular Toxicities Associated With
Ten Deaths Identified As Being Most Probably Related To Lemtrada, With Six Of These Cases Not Previously Reported, According To New Study   (Posted by Tom Lamb at DrugInjuryWatch.com)   UPDATE: “Dear Healthcare Professional Letter” sent  October 15, 2019 by sanofi-aventis Canada Inc.: LEMTRADA (alemtuzumab) – Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular Reactions (10/16/19)   Lemtrada adverse events have been on our radar for about the past year, and now…
Is Rhabdomyolysis A Side Effect For Aricept, Only, Or For Other Cholinesterase Inhibitors, Also?   (Posted by Tom Lamb at DrugInjuryWatch.com)   Back in January 2015 Health Canada issued a postmarket surveillance warning about a risk of rhabdomyolysis with Aricept (donepezil), a drug commonly used to manage cognitive decline in Alzheimer’s patients. More recently, this study was published online September 16, 2019 in CMAJ (Canadian Medical Association Journal), “Risk of rhabdomyolysis with donepezil
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study   (Posted by Tom Lamb at DrugInjuryWatch.com)   Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated with increased risks for pancreatic cancer in patients with newly diagnosed type 2 diabetes, according to an August 20, 2019 article published online by the Diabetes Care medical journal. These diabetes medicines are in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug…
At The Recent American Diabetes Association (ADA) Scientific Sessions There Was An Expression Of Doubt About Warnings For This Association   (Posted by Tom Lamb at DrugInjuryWatch.com)   In August 2018 the FDA required a new warning about an increased risk of developing Fournier’s gangrene (also known as necrotizing fasciitis of the perineum) be added to the drug labels for all SGLT2 inhibitor diabetes drugs. That regulatory action was based on 12 cases of…
“Black Box Warning” For Xeljanz 10 mg Twice Daily Dose Required By FDA In July 2019 Follows Regulatory Action In Europe   (Posted by Tom Lamb at DrugInjuryWatch.com)   A Xeljanz FDA Drug Safety Communication issued July 26, 2019 announced the addition of a so-called “Black Box Warning” about an increased risk of blood clots and death with the 10 mg twice daily dose of Xeljanz used by ulcerative colitis patients.  From the Safety…
New Drug Safety Warning: Uloric Should Be Avoided When There Is Prior Myocardial Infarction, Stroke, Or Unstable Angina   (Posted by Tom Lamb at DrugInjuryWatch.com)   From this Drug Safety Update issued July 17, 2019 by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), “Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease“, we get the following…
UK Drug Safety Regulator MHRA Imposes Lemtrada Use Restrictions And Mandates Patient Monitoring For Side Effects   (Posted by Tom Lamb at DrugInjuryWatch.com)   In May 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) took regulatory action regarding Lemtrada establishing new use restrictions and requiring increased monitoring of patients using this multiple sclerosis (MS) drug. From the introductory part of this May 17, 2019 MHRA Drug Safety Update, “Lemtrada (alemtuzumab) and
Serious Cases Of Hepatic Injury Some Of Which Have Resulted In Liver Transplant Or Death Reported As Side Effects   (Posted by Tom Lamb at DrugInjuryWatch.com)   On May 21, 2019 we posted this article, “Risk Of Actemra Associated Liver Injury Being Assessed By Health Canada, With Drug Label Change Likely To Follow“, which ended with this sentence:  “We will watch to see whether the FDA issues a similar drug safety warning…